NCT07285317CompletedPhase 1
Safety and Tolerability Evaluationof Phascolarcobacterium Faecium
Ensayo Exploratorio Para Evaluar la Tolerancia de Una Bacteria Con Potencial probiótico (Phascolarcobacterium Faecium) de Nueva generación Para Proteger la Salud metabólica en Humanos
Source: ClinicalTrials.gov · Last updated 16 Dec 2025
Brief summary (registry, in English)
The goal of this interventional study is to assess the safety and tolerability of the daily administratrion of bacterium Phascolarctobacterium faecium in healthy adults with normal weight, and in individuals with overweight and alterations in glucose metabolism. The main questions this study aims to answer are: Is the bacterium intake safe? Is the bacterium intake well tolerated? The objecitves are to assess if the intake of the bacterium is well tolerated by assessing gastrointenstinal symptoms, and safe, by assessing biochemical markers, incidence of adverse events and the general health status. Participants will take daily the bacterium for 15 days. Study assessments include stool collection for microbiota analysis; blood sampling form biochemical tests, anthropometric measurements, and validated questionnaires on diet, physical activity, and perceived health.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 14 Nov 2025
- Start date
- 1 Feb 2024
- Primary completion date
- 30 Jan 2025
- Lead sponsor
- Spanish National Research Council
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07285317
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- From 1 Feb 2024 to the primary completion date, 30 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- antibiotic use within one month before the study
- chronic antidiabetic therapy
- substance (drug) abuse
Other illness
- the presence of gastrointestinal disorders
- eating disorders
- any other condition deemed inappropriate for participation by the clinician
Other
- immunodeficiency
- restrictive diets
Who the study is looking for
- 18-65 years
- stable body weight and dietary habits during the previous three months
- written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto de Agroquímica y Tecnología de Alimentos (IATA-CSIC) Coordinator of this site? Confirm its status | Valencia | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.